![]() ![]() Opdivo is the world’s first approved and launched immune checkpoint inhibitor targeting PD-1. On July 4, 2014, Ono announced that Opdivo received manufacturing and marketing approval in Japan for the treatment of patients with unresectable melanoma, and sales of Opdivo started in Japan on Sept. Opdivo is an investigational PD-1 (programmed cell death-1) immune checkpoint inhibitor that binds to the checkpoint receptor PD-1 expressed on activated T-cells. The financial details of the agreement were not disclosed.Ĭancer cells may exploit "regulatory" pathways, such as checkpoint pathways, to hide from the immune system and shield the tumor from immune attack. "We are delighted to collaborate with Dako, a global leader in diagnostics, and this partnership contributes to value maximization of Opdivo," said Gyo Sagara, president, representative director and CEO, ONO. Today’s announcement follows several other collaborative agreements in the companion diagnostics area by Agilent’s Dako business," said Jacob Thaysen, president of Agilent's Diagnostics and Genomics Group. "We are pleased to be chosen as Ono’s partner for the development of a companion diagnostic test for this promising drug. The demand for personalized medicine continues to increase as it may provide a way to both improve patient care and better manage health care costs by targeting treatment to the individuals most likely to benefit from it. Lung cancer is the most common cause of cancer-related mortality worldwide, and is responsible for more than 1.5 million deaths per year1. ![]() This test is being investigated for its diagnostic utility to determine which patients are most likely to respond to Opdivo. ![]() (Ono) announced a new partnership to develop a potential diagnostic test specifically for use with Opdivo in the treatment of non-small cell lung cancer (NSCLC). Dako, an Agilent Technologies Company and a worldwide provider of cancer diagnostics, and Ono Pharmaceutical Co., Ltd. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |